Boston Scientific (NYSE:BSX) Given New $118.00 Price Target at Morgan Stanley

Boston Scientific (NYSE:BSX) had its price target lowered by research analysts at Morgan Stanley from $130.00 to $118.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical equipment provider’s stock. Morgan Stanley’s price objective indicates a potential upside of 56.29% from the company’s previous close.

Several other equities research analysts also recently issued reports on BSX. Canaccord Genuity Group set a $112.00 price target on shares of Boston Scientific in a research note on Thursday. Evercore ISI set a $112.00 target price on Boston Scientific in a research report on Monday, January 5th. Oppenheimer reduced their price target on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a report on Friday, January 16th. Mizuho dropped their price objective on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, BTIG Research reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $115.15.

Boston Scientific Price Performance

BSX stock opened at $75.50 on Thursday. The stock has a 50-day simple moving average of $94.37 and a 200-day simple moving average of $99.13. The firm has a market cap of $111.92 billion, a P/E ratio of 40.37, a price-to-earnings-growth ratio of 1.63 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific has a 1 year low of $75.00 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the prior year, the business earned $0.70 EPS. Boston Scientific’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts predict that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Boston Scientific

Several hedge funds have recently made changes to their positions in the stock. Steph & Co. acquired a new stake in Boston Scientific in the third quarter worth $25,000. Financial Consulate Inc. bought a new position in shares of Boston Scientific during the third quarter worth about $25,000. Murphy & Mullick Capital Management Corp increased its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter worth about $26,000. Finally, United Community Bank lifted its position in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS of $0.80 and $5.29B in revenue with ~16% reported sales growth and margin improvement, confirming underlying top‑line momentum. Boston Scientific announces results for fourth quarter and full year 2025
• Positive Sentiment: Operational growth and beat on consensus EPS give the company credibility that core businesses are expanding, supporting longer‑term revenue prospects. Boston Scientific (BSX) Beats Q4 Earnings and Revenue Estimates
• Neutral Sentiment: Wall Street still has a majority of buy ratings and an above‑current consensus price target, suggesting analysts may be cautious but not uniform in selling. MarketBeat BSX profile
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS and revenue ranges came in modest and slightly below consensus in places, and Q1 guidance was cautious — this trimmed near‑term growth expectations and triggered the selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Electrophysiology and a key hyped device underperformed expectations, prompting concern that some growth drivers will be weaker than modeled. Boston Scientific hits an 18-month low on a ‘sore spot’ for its most hyped device
• Negative Sentiment: Market reaction amplified by heavy bearish activity and a sharp intraday drop (including a 52‑week/18‑month low); options flow showed a surge in put buying, signaling short‑term bearish positioning. BSX Earnings: Boston Scientific Stock (BSX) Plunges 17% on Weak Guidance
• Negative Sentiment: Large insider sale disclosed (CEO sold ~160,901 shares), which may add to investor nervousness despite the company’s fundamentals. SEC filing: Insider sale by Michael Mahoney

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.